Latest Period
Q2 2026
Security Snapshot
Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) Institutional Ownership
CUSIP: 64136E102
13F Institutional Holders and Ownership History from Q4 2024 to Q2 2026
Institutions Reporting
22
Shares (Excl. Options)
1,993,993
Price
$4.37
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.00001 per share
- Symbol
- NEUP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 1,993,993
- Total 13F value
- $8,712,023
- Portfolio coverage rank
- 0%
- Share change
- +236,133
- Value change
- +$1,057,643
- Number of holders
- 22
- Shares outstanding
- 5,404,113
- SEC-reported price per share
- $3.81
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NEUP - Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 64136E102.
- 22 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 19 to 22 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $7,153,657 to $8,712,023.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 22 institutions filings for Q2 2026.
Security key
64136E102
Latest holder period
Q2 2026
13F holders
22
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
NEUP full holder history
Neuphoria Therapeutics Inc. SEC filings
Neuphoria Therapeutics Inc. company facts
Neuphoria Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 64136E102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
NEUP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5% | $5,365,401 | 1,033,796 | Armistice Capital, LLC | 31 Dec 2024 | |||
| Lynx1 Capital Management LP | 16% | 0% | $3,877,703 | 875,328 | 0% | Lynx1 Capital Management LP | 26 Dec 2025 | |
| Coastlands Capital LP | 4.2% | -17% | $992,007 | +$471,255 | 228,594 | +90% | Coastlands Capital LP | 23 Jul 2026 |
| Baselake Partners, LP | 4.1% | -59% | $862,110 | 222,222 | 0% | Baselake Partners, LP | 31 Dec 2025 | |
| Shay Capital LLC | 7.3% | $2,035,520 | 171,629 | Shay Capital LLC | 24 Oct 2025 | |||
| Apeiron Investment Group Ltd. | 4.5% | $376,887 | 72,618 | Apeiron Investment Group Ltd. | 24 Jan 2025 |
As of 30 Jun 2026, 22 institutional investors reported holding 1,993,993 shares of Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP). This represents 37% of the company’s total 5,404,113 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
37%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 16% | 875,328 | 0% | 0.44% | $3,825,183 |
| AdvisorShares Investments LLC | 4.7% | 252,909 | +63% | 0.13% | $1,105,212 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 173,488 | +76% | 0% | $758,143 |
| Shay Capital LLC | 2.9% | 155,822 | +3.2% | 0.08% | $680,942 |
| Balyasny Asset Management L.P. | 2.6% | 142,228 | +0.03% | 0% | $621,536 |
| CITADEL ADVISORS LLC | 1.3% | 72,559 | +275% | 0% | $317,083 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 49,516 | -4.8% | 0% | $216,384 |
| Ikarian Capital, LLC | 0.88% | 47,443 | 0% | 0.03% | $207,326 |
| VANGUARD FIDUCIARY TRUST CO | 0.63% | 33,806 | +0.65% | 0% | $147,732 |
| ADAR1 Capital Management, LLC | 0.56% | 30,000 | 0% | 0.01% | $131,100 |
| FNY Investment Advisers, LLC | 0.49% | 26,500 | 0% | 0.04% | $115,000 |
| RENAISSANCE TECHNOLOGIES LLC | 0.47% | 25,500 | 0% | $111,435 | |
| XTX Topco Ltd | 0.43% | 23,089 | 0% | $100,899 | |
| HRT FINANCIAL LP | 0.42% | 22,865 | 0% | $99,000 | |
| JANE STREET GROUP, LLC | 0.28% | 14,903 | 0% | $65,126 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.26% | 14,000 | 0% | 0% | $61,180 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.21% | 11,222 | 0% | 0% | $49,040 |
| NORTHERN TRUST CORP | 0.2% | 10,610 | 0% | $46,366 | |
| Merck & Co., Inc. | 0.19% | 10,027 | 0% | 0.01% | $43,818 |
| UBS Group AG | 0.04% | 2,117 | -8.6% | 0% | $9,251 |
| MORGAN STANLEY | 0% | 58 | 0% | 0% | $254 |
| Caitong International Asset Management Co., Ltd | 0% | 3 | 0% | $13 | |
| Virtu Financial LLC | 0% | 0 | -100% | $0 | |
| Squadron Capital Management LLC | 0% | 0 | -100% | $0 | |
| RHUMBLINE ADVISERS | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q2 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 1,993,993 | $8,712,023 | +$1,057,643 | $4.37 | 22 |
| 2026 Q1 | 1,757,860 | $7,153,657 | +$756,052 | $4.07 | 19 |
| 2025 Q4 | 1,465,999 | $5,687,252 | +$4,548,427 | $3.88 | 21 |
| 2025 Q3 | 195,338 | $2,303,036 | +$535,083 | $11.79 | 15 |
| 2025 Q2 | 177,963 | $1,263,538 | +$105,431 | $7.10 | 9 |
| 2025 Q1 | 163,114 | $935,356 | +$529,238 | $5.76 | 7 |
| 2024 Q4 | 79,719 | $273,435 | +$239,042 | $3.43 | 7 |